Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169804 | 0.84 | ALDH1A1 (0.47) | HSP90AA1HSP90AB1CYP3A4ALDH1A1HTT | |
| SCHEMBL10169808 | 0.82 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1LMNABCHEACHE | |
| SCHEMBL10169810 | 0.77 | USP5 (0.47) | HSP90AA1HSP90AB1ALDH1A1LMNAHTT | |
| SCHEMBL28246490 | 0.75 | EIF4A3 (0.40) | HSP90AA1HSP90AB1ALDH1A1LMNAHTT | |
| SCHEMBL25581220 | 0.75 | EIF4A3 (0.40) | HSP90AA1HSP90AB1ALDH1A1LMNAHTT | |
| SCHEMBL1164729 | 0.75 | SMN1; SMN2 (0.57) | ALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL16939770 | 0.74 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1ALDH1A1LMNABCHE | |
| Potassium SCHEMBL32667974 | 0.74 | SMN1; SMN2 (0.55) | ALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL13889408 | 0.74 | KMT2A (0.49) | HSP90AA1ALDH1A1HTT | |
| SCHEMBL1164773 | 0.71 | ABL1 (0.47) | ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106046-B2 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106046-B2 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFKB1, NFRKB | HSP90AA1 2710/4885HSP90AB1 1830/4885CYP3A4 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.